Application of double-liver-cancer molecular marker in preparation of liver cancer detection reagent product

By screening out DNA methylation dual liver cancer molecular markers suitable for early liver cancer detection and combining them with CpG methylation sites in specific genomic regions, the problem of insufficient sensitivity in existing liver cancer screening methods has been solved, achieving higher detection accuracy and stability, and making them suitable for early liver cancer detection in ex vivo blood samples.

CN118957073AActive Publication Date: 2024-11-15GUANGZHOU YOUZE BIOLOGICAL PHARM TECH CO LTD +1
View PDF 2 Cites 0 Cited by

Patent Information

Application Number
CN202411165512.3
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-23
Publication Date
2024-11-15
Estimated Expiration
2044-08-23

AI Technical Summary

Technical Problem

Existing liver cancer screening methods, such as AFP and ultrasound examination, are not sensitive enough, leading to missed detections. There is a need to develop more accurate and convenient liver cancer screening methods.

Method used

Two rounds of targeted methylation sequencing were used to screen for dual hepatocellular carcinoma molecular markers from human genome regions covered by more than 10 times the 450K chip. These markers were combined with CpG methylation sites in the chr2:25216400-25216752 and chr6:26250469-26250942 genomic regions to prepare hepatocellular carcinoma detection reagents, which were then used to develop a methylation-specific detection method.

Benefits of technology

It significantly improves the stability, sensitivity, and accuracy of liver cancer detection, enabling early detection of liver cancer and avoiding false positives and false negatives. It is suitable for testing in vitro blood samples and promotes early screening and diagnosis of liver cancer.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118957073A_ABST
    Figure CN118957073A_ABST
Patent Text Reader

Abstract

The invention discloses application of a double-liver-cancer molecular marker in preparation of a liver cancer detection reagent product, and belongs to the technical field of detection kits. The double-liver-cancer molecular marker is a DNA methylation double-liver-cancer molecular marker composition which is screened from a human genome region exceeding a 10-time 450K chip coverage range by the inventor through two rounds of targeted methylation sequencing and is suitable for early-stage liver cancer detection. The screened marker and the composition have the optimal detection performance, the detection accuracy can be further improved on the basis of a single methylation marker, and the problems of wrong detection and missing detection are avoided. Compared with a common liver cancer screening method, the double-liver cancer molecular marker has the advantages that the stability, the sensitivity and the accuracy are obviously improved, and the double-liver cancer molecular marker can be used for detecting an in-vitro blood sample and is very beneficial to popularization and popularization of early screening and early diagnosis of liver cancer.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention belongs to the technical field of detection kits, and in particular relates to an application of a dual liver cancer molecular marker in the preparation of a liver cancer detection reagent product. Background Art

[0002] "Early screening, early diagnosis and early treatment" of liver cancer is considered to be one of the important means to reduce the impact of liver cancer on patients and improve their survival rate, especially for small liver cancers less than 5 cm. The 5-year survival rate of patients treated early can reach more than 80%. However, the sensitivity of the commonly used liver cancer screening methods AFP and ultrasound examination is not ideal, resulting in a serious problem of missed detection. Therefore, the development of a more accurate and convenient liver cancer screening method is of great significance for the popularization and promotion of early liver cancer screening.

[0003] Abnormal DNA methylation signals are one of the characteristics of cancer. In recent years, studies have shown that the abnormal methylation signals carried by free DNA in the blood have good stability and can be used as molecular markers to detect the occurrence of cancer. Compared with blood AFP levels, free DNA methylation markers have higher sensitivity and specificity for liver cancer detection. Although some studies have preliminarily reported some free DNA methylation markers for liver cancer, most of these markers were screened from 450K methylation chip data, covering less than 2% of the methylation sites in the human genome.

[0004] Therefore, using more comprehensive marker screening strategies and methods is the key to developing more accurate HCC methylation markers. Summary of the invention

[0005] The purpose of the present invention is to provide an application of a dual liver cancer molecular marker in the preparation of a liver cancer detection reagent product. The inventor screened a composition of DNA methylation dual liver cancer molecular markers suitable for early liver cancer detection from a human genome region that is more than 10 times the coverage of a 450K chip through two rounds of targeted methylation sequencing. Compared with commonly used liver cancer screening methods, the dual liver cancer molecular marker has significantly improved stability, sensitivity and accuracy, and can be used for the detection of ex vivo blood samples, which is very beneficial to the promotion and popularization of early screening and diagnosis of liver cancer.

[0006] The present invention is achieved through the following technical solutions: A use of a dual liver cancer molecular marker in the preparation of a liver cancer detection reagent product, wherein the dual liver cancer molecular marker is a CpG methylation site in the chr2:25216400-25216752 and chr6:26250469-26250942 genomic region; The genomic region belongs to the hg38 human genome.

[0007] Preferably, the reagent product includes any one of a reagent, a kit, a chip, a hybridization probe and a sequencing library.

[0008] A double nucleic acid combination for detecting liver cancer, comprising a nucleic acid combination A for detecting, preferably, the CpG methylation level of the chr2:25216400-25216752 genomic region; and nucleic acid combination B for detecting the CpG methylation level of the chr6:26250469-26250942 genomic region.

[0009] Preferably, the nucleic acid combination A comprises a first primer pair combination and a first probe; The base sequence of the first primer pair combination has at least 90% similarity to the base sequence shown in SEQ ID NO: 1-2, SEQ ID NO: 4-5 or SEQ ID NO: 7-8; The base sequence of the first probe has at least 90% similarity with the base sequence shown in Sequence 3, Sequence 6 or Sequence 9.

[0010] Preferably, the nucleic acid combination B comprises a second primer pair combination and a second probe; The base sequence of the second primer pair combination has at least 90% similarity to the base sequence shown in SEQ ID NOs: 10-11, 13-14, 16-17 or 19-20; The base sequence of the second probe has at least 90% similarity to the base sequence shown in SEQ ID NO: 12, SEQ ID NO: 15, SEQ ID NO: 18 or SEQ ID NO: 21.

[0011] A kit for detecting liver cancer, comprising the dual liver cancer molecular markers or the dual nucleic acid combination for detecting liver cancer.

[0012] Preferably, the methylation level in the kit is detected by any one of the following methods: methylation-specific PCR method, methylation-specific microarray method, methylation sequencing method, methylation-specific high-performance liquid chromatography method, digital PCR method, methylation-specific high-resolution melting curve method.

[0013] Preferably, the sample detected in the kit includes any one of an ex vivo tissue sample, an ex vivo plasma sample, an ex vivo serum sample, an ex vivo whole blood sample, an ex vivo blood cell sample and a urine sample.

[0014] Compared with the prior art, the present invention has at least the following technical effects: (I) The present invention provides an application of a dual liver cancer molecular marker in the preparation of a liver cancer detection reagent product. The inventor screened out a composition of DNA methylation dual liver cancer molecular markers suitable for early liver cancer detection from a human genome region with more than 10 times the coverage of a 450K chip through two rounds of targeted methylation sequencing. In the sample data set used in the present invention, the screened markers and the composition have the best detection performance. Compared with the commonly used liver cancer screening methods, the dual liver cancer molecular marker has significantly improved stability, sensitivity and accuracy, and can be used for the detection of ex vivo blood samples, which is very beneficial to the promotion and popularization of early screening and diagnosis of liver cancer.

[0015] (ii) The kit for detecting liver cancer contains two DNA methylation markers. The dual liver cancer molecular marker combination is related to the occurrence of liver cancer. The combined results of the methylation levels of the two markers are suitable for assisting doctors in making judgments on whether early liver cancer has occurred.

[0016] (III) The kit uses DNA methylation dual liver cancer molecular markers. Compared with traditional tumor markers or liver cancer detection methods, DNA methylation dual liver cancer molecular markers have high detection sensitivity, more stable detection results, and are more likely to be detected in the early stages of cancer development, which is conducive to the discovery of liver cancer in the early stages of development. The kit uses a combination of methylation dual liver cancer molecular markers, which can further improve the detection accuracy on the basis of a single methylation marker and avoid the problems of false detection and missed detection.

[0017] (IV) The methylation sequencing used in the screening process of dual liver cancer molecular markers is based on the enzymatic conversion method to convert cytosine to uracil. Compared with the traditional bisulfite conversion, it can avoid damage to DNA, thereby solving the problem of low free DNA content in the blood. BRIEF DESCRIPTION OF THE DRAWINGS

[0018] Figure 1 The flowchart of the research and development of mining and screening of methylated dual liver cancer molecular markers for detecting liver cancer in Example 1; Figure 2 This is the ROC diagram for detecting the methylated dual liver cancer molecular marker composition in Example 3 in an in vitro blood sample of liver cancer. DETAILED DESCRIPTION

[0019] The embodiments of the present invention will be described in detail below in conjunction with examples. However, those skilled in the art will understand that the following examples are only used to illustrate the present invention and should not be construed as limiting the scope of the present invention. The specific conditions not specified in the examples are carried out according to conventional conditions or conditions recommended by the manufacturer. The reagents or instruments used without indicating the manufacturer are all conventional products that can be purchased commercially.

[0020] Example 1: Screening process of methylated double liver cancer molecular markers for liver cancer detection, the specific process is as follows Figure 1 shown.

[0021] This embodiment discloses a methylated dual liver cancer molecular marker composition for detecting early liver cancer and a screening process thereof.

[0022] In order to explore and screen methylated dual liver cancer molecular markers with excellent detection performance, this example first used a customized hybrid capture large panel for targeted methylation sequencing.

[0023] This hybridization capture panel covers 3.98 million CpG methylation sites in the human genome, including most of the CpG island regions and genes related to cancer occurrence, with a coverage range 10 times that of traditional DNA methylation chips.

[0024] By performing targeted sequencing on 82 clinical frozen tissue samples and 115 ex vivo blood samples and comparing the changes in methylation patterns between cancer and non-cancer groups, this example preliminarily identified 30,008 methylation sites that can clearly distinguish cancer and non-cancer samples in both tissue and blood samples as potential cancer markers.

[0025] Based on the 30,008 methylation sites initially screened above, a hybrid capture panel was designed for the second round of targeted methylation sequencing. This round of sequencing adopted a deep sequencing strategy, with an average sequencing depth of 500X, which significantly improved the accuracy of methylation level calculation and facilitated the accurate screening of markers in the second round. Targeted methylation sequencing was performed on ex vivo plasma samples of 218 clinical liver cancer patients and 196 ex vivo plasma samples of non-cancer groups, and univariate statistical analysis and machine learning methods were used to accurately screen out 12 DNA methylation markers with the best liver cancer detection performance.

[0026] Finally, primer and probe nucleic acid combinations of the qPCR detection platform were designed for the genomic regions of the 12 screened methylation markers, and the performance of liver cancer detection was verified on the qPCR platform using ex vivo plasma samples from 32 clinical liver cancer patients and 47 ex vivo plasma samples from non-cancer groups.

[0027] Finally, an exhaustive combination method was used to determine the combination of dual DNA methylation and dual liver cancer molecular markers with the best performance in liver cancer detection, namely the methylation levels of the chr2:25216400-25216752 and chr6:26250469-26250942 genomic regions.

[0028] The first primer pair combination for detecting the methylation level of the dual marker composition includes any one of sequences 1-2, 4-5 or 7-8; the second primer pair combination includes any one of sequences 10-11, 13-14, 16-17 or 19-20.

[0029] The first nucleic acid probe used for detection includes any one of sequence 3, sequence 6 or sequence 9; the second probe sequence includes any one of sequence 12, sequence 15, sequence 18 or sequence 21.

[0030] Example 2: Detection performance of the determined methylation dual liver cancer molecular marker in the methylation sequencing dataset of liver cancer tissue samples Targeted methylation sequencing was performed using 33 clinical liver cancer tissue samples and 49 non-cancer control tissue samples. The specific experimental steps are as follows: 1. Extraction of DNA samples: When the sample is a frozen fresh tissue sample, QIAGEN's "DNeasy® Blood & Tissue Kit #69506" is used to extract the genome. For specific operations, please refer to the kit instructions. Genomic DNA is interrupted using a Covaris M220 ultrasonic interrupter. When cfDNA is extracted from plasma samples, Guangzhou Youze Bio's "Free DNA Extraction Kit (Filtration Method) #C02-1" is used. For specific operations, please refer to the kit instructions.

[0031] 2. Use SPRIselect magnetic beads to screen the extracted DNA samples according to the recommended steps in the instructions, and filter out DNA molecules larger than 200 bp.

[0032] 3. Preparation of quality control products: 10 µL of 0.1 ng / µL CpG methylated pUC19 and 10 µL of 2 ng / µL unmethylated λ DNA should be added to each sample.

[0033] 4. Library construction for methylation sequencing: Use the NEBNext Enzymatic Methyl-Seq kit to construct the library.

[0034] 4.1 End repair and 3' end addition of "A" 4.1.1 Take 50 ng of the sample to be tested, dilute it to 50 μL with NF water, and then add the following reagents for reaction.

[0035]

[0036] 4.1.2 Place in PCR instrument and perform reaction according to the following procedure

[0037] 4.2 Connector connection 4.2.1 Add the following reagents to the end repair product for reaction

[0038] 4.2.2 Place in a PCR instrument and set the PCR reaction program according to the following conditions: 60°C, 60 min, with the heated lid closed.

[0039] 4.2.3 Purification of adapter ligation products A. Equilibrate the purified magnetic beads at room temperature for 30 minutes and mix them thoroughly on a vortex.

[0040] B. Prepare 80% ethanol according to the ratio of anhydrous ethanol to nuclease-free water = 8:2 and set aside.

[0041] C. Add 55 μL of purified magnetic beads to each ligation product, mix well by pipetting, incubate at room temperature for 5 minutes, place on a magnetic rack, and discard the supernatant after the solution is clarified; wash with freshly prepared 80% ethanol, discard the supernatant, and repeat this step once; dry, elute with 15 μL of elution buffer, and aspirate 14 μL of supernatant for the next reaction.

[0042] 4.3 Methylation: Oxidation reaction 4.3.1 Buffer configuration: a. Add 400 μL of E1 reaction buffer to 100 μL of E1 reaction buffer supplement, shake and mix thoroughly, and mark the preparation date.

[0043] b Take 10 μL of 500 mM Fe (II) and add it to 1249 μL of nuclease-free water. The diluted solution should be used immediately and should not be stored.

[0044] c Dilute the Stop Buffer 1:10 with nuclease-free water.

[0045] 4.3.2 Add the following reagents to 14 μL of the purified ligation product and mix well. Then add 10 μL of diluted Fe(II) to the purified ligation product to which the oxidase has been added, mix well and centrifuge.

[0046]

[0047] 4.3.3 Place the tube in a PCR instrument and react under the following conditions: 37°C, 1h, heating cover temperature ≥ 45°C.

[0048] 4.3.4 After the reaction is completed, add 1 μL of the diluted reaction stop solution to the product and place it on the PCR instrument for reaction under the following conditions: 37°C, 30 min, hot cover temperature ≥ 45°C.

[0049] 4.3.5 Purification of oxidation reaction products A. Equilibrate the purified magnetic beads at room temperature for 30 minutes and thoroughly mix them on a vortex machine; B. Prepare 80% ethanol in a ratio of 8:2 for absolute ethanol and nuclease-free water, and set aside. C. Add 45 μL of NEB Next Sample purified magnetic beads to each ligation product, mix well by pipetting, incubate at room temperature for 5 minutes, place on a magnetic rack, and discard the supernatant after the solution is clarified; wash with freshly prepared 80% ethanol, discard the supernatant, and repeat this step once; dry, elute with 9.5 μL of elution buffer, and aspirate 8 μL of supernatant for the next reaction.

[0050] 4.4 Methylation: cytosine deamination 4.4.1 Denaturation: a. Preheat the PCR instrument to 85°C and open the heated cover; b Add 2 μL of formamide to 8 μL of the purified oxidation reaction product, vortex to mix, and centrifuge briefly.

[0051] 4.4.2 Add the following reagents to the denatured product for reaction

[0052] 4.4.3 Place in PCR instrument and react under the following conditions: 37℃, 3h, heating cover temperature ≥ 45℃.

[0053] 4.4.4 Purification of Cytosine Deamination Reaction Products a. Equilibrate the purified magnetic beads at room temperature for 30 minutes and thoroughly mix them on a vortex machine; b Prepare 80% ethanol according to the ratio of anhydrous ethanol to nuclease-free water = 8:2 and set aside; c. Add 50 μL of NEB Next Sample purified magnetic beads to each ligation product, mix well by pipetting, incubate at room temperature for 5 minutes, place on a magnetic rack, and discard the supernatant after the solution is clarified; wash with freshly prepared 80% ethanol, discard the supernatant, and repeat this step once; dry, elute with 11 μL of elution buffer, and aspirate 10 μL of supernatant for the next reaction.

[0054] 4.5 PCR amplification and purification 4.5.1 Add the following reagents to the above purified product for reaction

[0055] 4.5.2 Place on PCR instrument and react according to the following conditions

[0056] 4.5.3 Purification of PCR amplification products a. Equilibrate the purified magnetic beads at room temperature for 30 minutes and thoroughly mix them on a vortex machine; b Prepare 80% ethanol in the ratio of anhydrous ethanol to nuclease-free water = 8:2 and set aside; c. Add 22.5 μL of NEB purified magnetic beads to each ligation product, mix well by pipetting, incubate at room temperature for 5 minutes, place on a magnetic rack, and discard the supernatant after the solution is clarified; wash with freshly prepared 80% ethanol, discard the supernatant, and repeat this step once; dry, elute with 15 μL of elution buffer, aspirate 14 μL of supernatant, and conduct quality inspection.

[0057] 5. Hybridization and elution 5.1 Hybridization: a Take 10 ng of each library to be hybridized, calculate the library volume required for combined hybridization, and mix the 12 libraries together; b. Add the following reagents to the library mixture for reaction; c Turn on the vacuum concentrator, set the V-AQ mode, and concentrate into dry powder at room temperature; d. Immediately take 20 μL of hybridization mixture and add it to the concentrated dry powder, mix well and let it stand at room temperature for 5 minutes, then add 30 μL of hybridization enhancement solution, mix well and centrifuge; e Place on a PCR instrument and perform the reaction under the following conditions.

[0058] Reagent composition table

[0059] PCR reaction conditions table

[0060] 5.2 Capture and elution 5.2.1 Buffer preheating: Preheat the rapid binding solution and rapid washing solution 2 at 48°C until the precipitate is dissolved, and preheat the rapid washing solution 1 at 63°C until the precipitate is dissolved. Equilibrate the streptavidin magnetic beads at room temperature for at least 30 minutes.

[0061] 5.2.2 Magnetic bead capture a Vortex to mix the streptavidin magnetic beads that have been equilibrated to room temperature; b. Take 70 μL of streptavidin magnetic beads and add them into a 1.5 mL centrifuge tube; c. Add 20 μL of binding buffer, mix by pipetting, centrifuge briefly, place on a magnetic stand, let stand for 1 min, and discard the supernatant; d. Repeat steps b and c twice, performing streptavidin magnetic bead washing three times in total; e Add 20 μL binding buffer to resuspend the streptavidin magnetic beads; f Transfer 20 μL of resuspended streptavidin magnetic beads to the hybridization reaction tube, and then transfer all the liquid to a 1.5 mL centrifuge tube.

[0062] g. Mix on a mixer at room temperature for 30 minutes without vortexing. h After mixing, centrifuge immediately, place on a magnetic stand, let stand for 1 minute, and discard the supernatant.

[0063] 5.2.3 Elution a. Add 200 μL of 54°C preheated rapid wash buffer 1, mix well by pipetting, and incubate in a thermostatic metal bath at 54°C for 5 min; b After the incubation is completed, centrifuge briefly and transfer all the liquid to a new 1.5 mL centrifuge tube to remove the non-specific capture fragments bound to the surface of the centrifuge tube; c Place on a magnetic stand, let stand for 1 minute, and discard the supernatant; d. Add 200 μL of 63°C preheated washing buffer 1, pipette to mix, and incubate in a thermostatic metal bath at 54°C for 5 min. e After incubation, centrifuge immediately, place on a magnetic stand, let stand for 1 min, and discard the supernatant; f. Add 200 μL of 54°C preheated washing buffer 2, pipette to mix, and incubate in a thermostatic metal bath at 54°C for 5 minutes; g After the incubation is completed, centrifuge briefly, place on a magnetic stand, let stand for 1 minute, and discard the supernatant; h. Repeat steps a to g twice for a total of three washes; i Centrifuge briefly, discard the remaining supernatant with a 10 μL pipette tip, immediately add 45 μL of nuclease-free water, pipette to mix, and incubate on ice.

[0064] 5.3 PCR enrichment of capture products 5.3.1 Take 22.5 μL of the captured product (streptavidin magnetic bead suspension) and add the following reagents to react.

[0065]

[0066] Place on PCR instrument and react according to the following conditions

[0067] 5.3.2 PCR product purification a. Equilibrate the DNA purification magnetic beads at room temperature for 30 minutes and mix thoroughly on a vortex machine; b Prepare 80% ethanol in the ratio of anhydrous ethanol to nuclease-free water = 8:2 and set aside; c. Add 90 μL of DNA purification magnetic beads to each ligation product, mix well by pipetting, incubate at room temperature for 5 minutes, place on a magnetic rack, discard the supernatant after the solution is clarified; wash with freshly prepared 80% ethanol, discard the supernatant, repeat this step once; dry, elute with 32 μL of elution buffer, aspirate 30 μL of supernatant for quality control, and sequence on the machine.

[0068] 6. Analysis of sequencing data: The raw data was first filtered using fastQC to filter low-quality sequences (phred33 score ≤ 20) and adapter sequences and polyA / T sequences in the reads. The filtered high-quality reads were mapped to the hg38 human genome using BSMAP, and reads with high mapping quality were screened out. After removing PCR duplicates using picard, reads mapped to the target genomic region (the region corresponding to the DNA methylation marker) were selected using samtools and the methylation levels of each DNA methylation marker were calculated.

[0069] The detection performance of the determined methylation markers for distinguishing liver cancer tissues from non-cancer tissues is shown in the following table.

[0070] Example 3: Performance of the identified methylation markers in a liver cancer ex vivo blood sample methylation sequencing dataset Targeted methylation sequencing was performed using ex vivo blood samples collected from 218 clinical liver cancer patients and 196 non-cancer controls, and the methylation levels of each methylation marker were calculated. Single methylation markers were subjected to univariate statistical analysis to calculate the detection performance of ex vivo blood samples for distinguishing liver cancer patients from controls. Liver cancer was predicted by combining the determined chr2:25216400-25216752 and chr6:26250469-26250942 dual markers, and the detection performance of the dual marker combination was statistically analyzed.

[0071] like Figure 2 As shown, the AUC value of the determined methylation marker composition for methylation sequencing detection of liver cancer ex vivo blood samples is 0.951; the detection sensitivity and specificity are as follows:

[0072] Example 4: Performance of the identified methylation markers in a liver cancer ex vivo blood sample qPCR detection dataset The primer and probe combinations required for the methylation qPCR detection platform were designed for the determined chr2:25216400-25216752 and chr6:26250469-26250942 double markers, and the design results are as follows:

[0073] The collected blood samples from 32 clinical liver cancer patients and 47 non-cancer control groups were used for methylation qPCR detection, and the qPCR detection Ct values ​​were recorded. The specific experimental steps are as follows: 1. Separation of plasma: First, centrifuge the collected 10 mL clinical blood sample at 1600×g for 10 minutes to separate the plasma. Centrifuge the separated plasma at 16000×g for 10 minutes to separate impurities. The purified plasma sample should be stored in a -80℃ refrigerator for future use.

[0074] 2. Free DNA extraction: Use the "Free DNA Extraction Kit" (Cat. No.: C03-2) of Guangzhou Youze Biotechnology Co., Ltd. to extract plasma free DNA from the separated plasma samples.

[0075] 3. Free DNA conversion: Use ZYMO's "EZ-96 DNA Methvlation-Lightning MagPrep" to perform methylation C->T conversion on the extracted free DNA samples.

[0076] 4. Negative and positive controls for methylation quantitative PCR: The negative control was the genomic DNA of the cell line (cell line: QSG-7701) transformed by the ZYMO kit, with a concentration of 1 ng / μL. After transformation, the C in the negative control was changed to T. The positive control was the genomic DNA of the cell line (cell line: HepG2) transformed by bisulfite using the ZYMO kit, with a concentration of 1 ng / μL. After transformation, the C at the methylated CpG position did not change, and the C at other positions was changed to T.

[0077] 5. Reaction system for methylation quantitative PCR:

[0078] 6. Reaction procedure of methylation quantitative PCR:

[0079] 7. On-machine detection: Mix the sample DNA to be tested, negative reference, and positive reference according to the reaction system of methylation quantitative PCR in step 5. Put the sample into Shanghai Hongshi SLAN-96S quantitative PCR instrument, and set up the quantitative PCR instrument according to the program conditions in step 6 for detection, and collect the fluorescence values ​​of each channel of HEX / ROX / FAM / CY5.

[0080] 8. Result recording: After the methylation quantitative PCR reaction is completed, the threshold is set at the inflection point of the S-type amplification curve to obtain the Ct value of the sample to be tested at the methylation site.

[0081] 9. Quality control: Negative and positive references are tested simultaneously in each test. The negative control is the transformed cell genomic DNA (cell line: QSG-7701) containing the β-actin gene and the low-methylation target gene sequence, and the positive control is the transformed cell cfDNA (cell line: HepG2) containing the β-actin gene and the high-methylation target gene sequence, both at a concentration of 1ng / μL. When the negative reference is not amplified, the Ct value of the positive reference is between 28-32, and the Ct value of the internal reference gene is less than 38, the experiment is valid and the next step of sample result determination can be carried out. Otherwise, the result is invalid and the test must be repeated.

[0082] 10. Result determination: If the Ct value of the target marker is less than 35, the test result is positive, otherwise the test result is negative. When multiple markers are combined for joint determination, if at least one target marker's Ct value is less than 35, the test result is positive, otherwise the test result is negative.

[0083] The designed primer-probe combination was used to perform qPCR detection of CT values ​​in ex vivo blood samples to distinguish liver cancer and non-cancer samples. The detection performance is shown in the following table:

[0084] From the results of plasma qPCR test, it can be seen that the detection sensitivity of ex vivo blood samples of liver cancer using chr2:25216400-25216752 or chr6:26250469-26250942 methylation markers is 81.3% to 84.4%, and the specificity is about 90%. When combined with dual methylation markers, the detection sensitivity can be increased to 87.5-93.8%, and the specificity remains at about 90%.

[0085] Finally, it should be noted that the above description is only a preferred embodiment of the present invention and is not intended to limit the protection scope of the present invention. Any modification, equivalent replacement, improvement, etc. made within the spirit and principle of the present invention shall be included in the protection scope of the present invention.

Claims

1. An application of a dual liver cancer molecular marker in the preparation of a liver cancer detection reagent product, characterized in that: The dual liver cancer molecular markers are CpG methylation sites in the genomic regions of chr2:25216400-25216752 and chr6:26250469-26250942; The genomic region belongs to the hg38 human genome.

2. The use of a dual liver cancer molecular marker according to claim 1 in the preparation of a liver cancer detection reagent product, characterized in that: The reagent product is any one of a reagent, a kit, a chip, a hybridization probe and a sequencing library.

3. A dual nucleic acid combination for detecting liver cancer, characterized in that: Comprising a nucleic acid combination A for detecting the CpG methylation level of the chr2:25216400-25216752 genomic region as claimed in claim 1; and nucleic acid combination B for detecting the CpG methylation level of the chr6:26250469-26250942 genomic region.

4. A dual nucleic acid combination for detecting liver cancer according to claim 3, characterized in that: The nucleic acid combination A includes a first primer pair combination and a first probe; The base sequence of the first primer pair combination has at least 90% similarity to the base sequence shown in SEQ ID NO: 1-2, SEQ ID NO: 4-5 or SEQ ID NO: 7-8; The base sequence of the first probe has at least 90% similarity with the base sequence shown in Sequence 3, Sequence 6 or Sequence 9.

5. A dual nucleic acid combination for detecting liver cancer according to claim 3, characterized in that: The nucleic acid combination B includes a second primer pair combination and a second probe; The base sequence of the second primer pair combination has at least 90% similarity to the base sequence shown in SEQ ID NOs: 10-11, 13-14, 16-17 or 19-20; The base sequence of the second probe has at least 90% similarity to the base sequence shown in SEQ ID NO: 12, SEQ ID NO: 15, SEQ ID NO: 18 or SEQ ID NO:

21.

6. A kit for detecting liver cancer, characterized in that: The kit comprises the dual liver cancer molecular markers as described in claim 1 or the dual nucleic acid combination for detecting liver cancer as described in any one of claims 3-4.

7. A kit for detecting liver cancer according to claim 6, characterized in that: The methylation level in the kit is detected by any of the following methods: methylation-specific PCR method, methylation-specific microarray method, methylation sequencing method, methylation-specific high-performance liquid chromatography method, digital PCR method, and methylation-specific high-resolution melting curve method.

8. A kit for detecting liver cancer according to claim 6, characterized in that: The sample detected in the kit includes any one of an ex vivo tissue sample, an ex vivo plasma sample, an ex vivo serum sample, an ex vivo whole blood sample, an ex vivo blood cell sample and a urine sample.

Citation Information

Patent Citations

  • Molecular marker detection kit for primary liver cancer, nucleic acid composition and application

    CN113846167A

  • Biomarker, nucleic acid product and kit for liver cancer

    CN114941029A